Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16897487 | 1.00 | OPRM1 (0.50) | OPRM1OPRL1ACHEBACE1ADRA1D | |
| SCHEMBL16897590 | 1.00 | OPRM1 (0.50) | OPRM1OPRL1ACHEBACE1ADRA1D | |
| SCHEMBL28088799 | 0.89 | OPRM1 (0.53) | OPRM1OPRL1ACHEBACE1SMN1; SMN2 | |
| SCHEMBL5465979 | 0.82 | ALDH1A1 (0.53) | OPRM1OPRL1 | |
| SCHEMBL5470962 | 0.82 | ALDH1A1 (0.53) | OPRM1OPRL1 | |
| SCHEMBL5465983 | 0.82 | ALDH1A1 (0.53) | OPRM1OPRL1 | |
| SCHEMBL9044015 | 0.80 | OPRM1 (0.53) | OPRM1OPRL1ACHEBACE1BCHE | |
| SCHEMBL3644107 | 0.79 | OPRM1 (0.52) | OPRM1OPRL1ACHEBACE1BCHE | |
| SCHEMBL18854347 | 0.78 | OPRM1 (0.62) | OPRM1OPRL1ACHEBACE1SMN1; SMN2 | |
| SCHEMBL18854346 | 0.78 | OPRM1 (0.62) | OPRM1OPRL1ACHEBACE1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092239-B1 | ARYL SULTAM DERIVATIVES AS RORC MODULATORS | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | disclosed |
| EP-3092239-B1 | ARYL SULTAM DERIVATIVES AS RORC MODULATORS | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | disclosed |
| US-10131644-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170137393-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137393-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3092239-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104354-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104354-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131644-B2 | Aryl sultam derivatives as RORc modulators | RORC, RORB, RORA | OPRM1 56/4885OPRL1 521/4885ACHE 3734/4885 |
| US-20170137393-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | OPRM1 56/4885OPRL1 521/4885ACHE 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.